📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Orchasp Ltd Approves Q3 Results with Qualified Audit Opinion and Major Board Reconstitution
Orchasp Limited has approved its unaudited financial results for the quarter ended December 31, 2025, which notably received a qualified opinion from statutory auditors. The company is undergoing a significant board transition with the appointment of two new directors, including the sister of the current MD & CFO as a Non-Executive Director. Simultaneously, three Independent Directors are scheduled to exit the board between February and March 2026 following the completion of their tenures. This has led to a full reconstitution of the Audit, Nomination, and Stakeholders Relationship committees.
Key Highlights
Statutory auditors JMT & Associates issued a qualified opinion on the Q3 FY2025-26 financial results.
Mr. Srinivasu Sunkara appointed as Independent Director for a 5-year term effective February 10, 2026.
Ms. Sirisha Pattapurathi, sister of MD & CFO P. Chandra Sekhar, appointed as Non-Executive Non-Independent Director.
Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Srinivasa Reddy, and Mr. Sai Roopkumar Vegunta) to cease office by March 6, 2026.
Board committees including Audit and Stakeholders Relationship reconstituted effective February 10, 2026.
💼 Action for Investors
Investors should exercise caution and specifically review the 'qualified opinion' in the financial statements to understand the auditor's concerns. The simultaneous exit of three independent directors and the appointment of a promoter-related director warrant close monitoring of corporate governance standards.
Orchasp Ltd Appoints New Directors; Q3 FY26 Results Receive Qualified Auditor Opinion
Orchasp Limited has announced a significant board reshuffle, appointing Mr. Srinivasu Sunkara as an Independent Director for a five-year term and Ms. Sirisha Pattapurathi as a Non-Executive Director. These appointments coincide with the upcoming departure of three Independent Directors between February and March 2026. Notably, the company's Q3 FY26 financial results were approved but received a qualified opinion from the statutory auditors, JMT & Associates. Investors should note that Ms. Pattapurathi is the sister of the current Managing Director and CFO.
Key Highlights
Appointment of Mr. Srinivasu Sunkara as Independent Director for a 5-year term ending February 2031.
Ms. Sirisha Pattapurathi appointed as Non-Executive Director; she is the sister of the MD & CFO.
Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Reddy, and Mr. Sai Vegunta) to exit by March 6, 2026.
Statutory auditors issued a qualified opinion on the unaudited financial results for the quarter and nine months ended December 31, 2025.
Board committees, including Audit and Nomination, were reconstituted effective February 10, 2026.
💼 Action for Investors
Investors should carefully review the specific reasons behind the auditor's qualified opinion in the Q3 results to assess financial transparency risks. Monitor how the significant turnover in independent directors affects the company's corporate governance standards.
Orchasp Ltd Q3 FY26 Results Approved; Board Reconstituted Amid Auditor Qualification
Orchasp Limited has approved its Q3 FY26 financial results, which notably received a qualified opinion from statutory auditors JMT & Associates. The company is undergoing a major board transition with the appointment of Mr. Srinivasu Sunkara as an Independent Director and Ms. Sirisha Pattapurathi as a Non-Executive Director. This follows the upcoming cessation of three independent directors—Ms. Ponnari Gottipati, Mr. Bade Srinivasa Reddy, and Mr. Sai Roopkumar Vegunta—by March 2026. Consequently, the Audit and other board committees have been reconstituted to align with the new leadership structure.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Statutory auditors issued a qualified opinion on the financial statements, indicating potential accounting concerns.
Appointed Mr. Srinivasu Sunkara as Independent Director for a five-year term ending February 2031.
Ms. Sirisha Pattapurathi, sister of the MD & CFO, appointed as a Non-Executive Non-Independent Director.
Three Independent Directors to step down by March 2026 upon completion of their respective terms.
💼 Action for Investors
Investors should exercise caution and investigate the specific nature of the auditor's qualified opinion. The significant turnover in independent directors and the appointment of a promoter relative to the board suggest a need for heightened monitoring of corporate governance.
Orchasp's INDUSAYUSH Health Platform Now Live on Google Play Store
Orchasp Limited has announced the successful admission of its electronic health records (EHR) platform, INDUSAYUSH, on the Google Play Store effective December 31, 2025. This launch represents a key milestone in the company's digital healthcare strategy, providing broader access to its services for Android users. The availability of the app is expected to facilitate user acquisition and enhance the visibility of the company's healthcare technology offerings. Investors should note this as a positive step toward scaling their digital product portfolio.
Key Highlights
INDUSAYUSH electronic health records platform admitted to Google Play Store on December 31, 2025
Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The app is now publicly accessible for download, marking a transition from development to market availability
Move aims to strengthen the company's footprint in the digital health and EHR management sector
💼 Action for Investors
Investors should monitor the app's download growth and user reviews to gauge market adoption. It is also important to look for upcoming management commentary regarding the monetization plan for the INDUSAYUSH platform.
Orchasp Allots 2.68 Crore Equity Shares at Rs 3.20 to Settle Debt
Orchasp Limited has approved the allotment of 2,68,75,000 equity shares on a preferential basis at an issue price of Rs 3.20 per share. These shares are being issued to Mrs. P. Rajeswari, the legal heir of the company's former Chairman & CEO, Mr. P.C. Pantulu. The allotment serves to convert outstanding loan amounts into equity, effectively reducing the company's debt liabilities. While this move results in equity dilution, it improves the company's balance sheet by settling debt without cash outflow.
Key Highlights
Allotment of 2,68,75,000 equity shares with a face value of Rs 2 each.
Preferential allotment price set at Rs 3.20 per share.
Shares issued to settle outstanding loan amounts of the late ex-Chairman & CEO.
Total transaction value for debt-to-equity conversion is approximately Rs 8.6 crore.
Board has authorized the Managing Director to proceed with listing and trading permissions.
💼 Action for Investors
Investors should view the debt reduction as a positive for the company's financial health, though they should be mindful of the resulting equity dilution. Monitor the company's upcoming quarterly results to see the impact of reduced interest burdens.
Orchasp receives in-principle approval for equity share issue
Orchasp Limited has received in-principle approval from the NSE for issuing equity shares of ₹2 each under preferential terms. The approval is subject to the company fulfilling several conditions, including filing the listing application promptly and complying with regulations from SEBI, RBI, and MCA. The NSE has also advised Orchasp to strengthen internal controls to monitor trading by allottees and ensure compliance with SEBI (ICDR) Regulations. Investors should monitor the company's progress in fulfilling these conditions and ensure compliance with regulatory requirements.
Key Highlights
In-principle approval for issue of Equity shares of Rs. 2/- each
Compliance with SEBI (LODR) Regulations, 2015
Compliance with Companies Act, 1956 / Companies Act, 2013
Company advised to strengthen internal controls before allotment of securities
💼 Action for Investors
Investors should monitor Orchasp's compliance with the conditions set by NSE and SEBI. Watch for the filing of the listing application and adherence to regulatory guidelines.
Orchasp to Incorporate Wholly-Owned Subsidiary 'Orchasp Inc' in USA
Orchasp Limited is expanding its operations by incorporating a wholly-owned subsidiary named "Orchasp Inc" in the USA. This decision follows a board evaluation that found the cost of reviving the dormant Cybermate Infotek Limited Inc subsidiary to be higher than creating a new one. The new subsidiary will focus on marketing the indusayush health care platform and enabling the mobile app on android and ios playstore. The proposed share capital for Orchasp Inc is 10,000 shares at USD 1 each, totaling USD 10,000.
Key Highlights
Incorporating a wholly-owned subsidiary in USA named “Orchasp Inc”.
Proposed share capital of 10,000 Shares of USD 1 each.
Total investment of USD 10,000 in the new subsidiary.
💼 Action for Investors
Investors should monitor the performance of the new subsidiary and its impact on Orchasp's overall revenue and profitability. Keep an eye on the adoption and market penetration of the indusayush platform in the US market.